Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...
Regeneron price target lowered to $925 from $950 at Oppenheimer
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Sanofi treatment of immunoglobulin G4-related disease granted orphan status
US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...